Study guide

10.2 Glycolysis, Pyruvate Dehydrogenase, TCA Cycle, and Oxidative Phosphorylation

NPLEX Part I — Biomedical Sciences Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Pacing, and GEA Strategy

1.1 Overview of NPLEX Part I & NABNE Exam Structure 1.2 Deconstructing Biomedical Clinical Vignettes 1.3 General Exam Areas (GEAs) & Passing Standards

2 Chapter 2: Gross Anatomy & Musculoskeletal System

2.1 Musculoskeletal Anatomy of Upper and Lower Extremities 2.2 Structural Anatomy of Head, Neck, Thorax, and Abdomen 2.3 Pelvic Architecture, Perineal Anatomy, and Articular Structures

3 Chapter 3: Histology & Microscopic Anatomy

3.1 Histology of Epithelial, Connective, and Muscular Tissues 3.2 Microscopic Structure of Gastrointestinal, Renal, and Endocrine Organs 3.3 Microscopic Anatomy of Integument, Lymphoid Tissues, and Respiratory Epithelium

4 Chapter 4: Neuroanatomy & Special Senses

4.1 Cranial Nerves, Nuclei, and Peripheral Distribution 4.2 Spinal Cord Tracts, Brainstem Circuits, and Motor/Sensory Pathways 4.3 Cerebral Cortex, Basal Ganglia, Limbic System, and Autonomic Nervous System 4.4 Neuroanatomy of Vision, Audition, Vestibular Function, and Olfaction/Gustation

5 Chapter 5: Embryology & Developmental Anatomy

5.1 Gametogenesis, Fertilization, Blastulation, and Germ Layer Derivatives 5.2 Organogenesis: Cardiovascular and Respiratory System Development 5.3 Gastrointestinal, Urogenital, and Craniofacial Embryology

6 Chapter 6: Cellular & General Physiology

6.1 Membrane Transport Mechanics, Resting Potentials, and Ion Channels 6.2 Action Potential Propagation and Synaptic Transmission 6.3 Excitation-Contraction Coupling in Skeletal, Cardiac, and Smooth Muscle

7 Chapter 7: Cardiovascular & Respiratory Physiology

7.1 Cardiac Electrophysiology, ECG, and Mechanical Cardiac Cycle 7.2 Hemodynamics, Peripheral Resistance, and Blood Pressure Control 7.3 Pulmonary Mechanics, Lung Volumes, and Gas Exchange Dynamics 7.4 Transport of Oxygen/CO2 and Neural/Chemical Control of Breathing

8 Chapter 8: Renal, Fluid, & Acid-Base Physiology

8.1 Glomerular Filtration Rate and Tubular Reabsorption/Secretion Mechanics 8.2 Countercurrent Multiplication, Osmoregulation, and Urine Concentration 8.3 Body Fluid Compartments, Sodium/Water Homeostasis, and Potassium Dynamics 8.4 Renal & Respiratory Acid-Base Regulation and Compensation Mechanisms

9 Chapter 9: Gastrointestinal, Endocrine, & Reproductive Physiology

9.1 GI Motility, Secretory Functions, Digestion, and Nutrient Absorption 9.2 Hypothalamic-Pituitary Axes, Adrenal Gland, and Thyroid Physiology 9.3 Endocrine Pancreas, Glucose Regulation, Calcium/Phosphate Homeostasis 9.4 Male and Female Reproductive Endocrinology and Menstrual Cycle Regulation

10 Chapter 10: Enzymology, Bioenergetics, & Carbohydrate/Lipid Metabolism

10.1 Enzyme Kinetics, Catalytic Mechanisms, and Vitamin Cofactors 10.2 Glycolysis, Pyruvate Dehydrogenase, TCA Cycle, and Oxidative Phosphorylation 10.3 Glycogen Metabolism, Gluconeogenesis, and Pentose Phosphate Pathway 10.4 Fatty Acid Synthesis, Beta-Oxidation, Ketogenesis, and Lipoprotein Transport

11 Chapter 11: Amino Acid/Nucleotide Metabolism & Clinical Genetics

11.1 Amino Acid Degradation, Transamination, and Urea Cycle Disorders 11.2 Purine and Pyrimidine Synthesis, Salvage, and Gout Pathophysiology 11.3 Mendelian Inheritance, Chromosomal Abnormalities, and Molecular Genetics

12 Chapter 12: Immunology & Immunopathology

12.1 Innate Immune Barriers, Phagocytosis, Cellular Pattern Recognition, and Complement System 12.2 Adaptive Immunity: T-Cell & B-Cell Activation, MHC Restriction, and Antibodies 12.3 Types I-IV Hypersensitivity Reactions and Mechanisms of Autoimmunity 12.4 Immunodeficiency Syndromes, Tumor/Transplant Immunology, and Vaccine Types

13 Chapter 13: Medical Microbiology

13.1 Medical Bacteriology: Gram-Positive, Gram-Negative, and Atypical Bacteria 13.2 Medical Virology: DNA, RNA, Retroviruses, and Viral Pathogenesis 13.3 Medical Mycology: Cutaneous, Systemic, and Opportunistic Fungal Infections 13.4 Medical Parasitology: Protozoan and Helminthic Pathogens

14 Chapter 14: General Pathology & Neoplasia

14.1 Cellular Adaptation, Reversible/Irreversible Injury, Necrosis, and Apoptosis 14.2 Acute and Chronic Inflammation, Chemical Mediators, and Tissue Healing 14.3 Neoplasia: Benign vs Malignant Features, Carcinogenesis, Oncogenes, and Tumor Suppressors

15 Chapter 15: Systems Pathology & Disease Mechanisms

15.1 Pathophysiology of Atherosclerosis, Heart Failure, COPD, and Pneumonias 15.2 Glomerulonephritis, Inflammatory Bowel Disease, and Hepatorenal Disease Pathophysiology 15.3 Endocrine Disorders, Neurodegenerative Pathology, and Epidemiological Principles 15.4 Hematopoietic System Pathology: Anemias, Coagulopathies, and Hematologic Neoplasms 15.5 Immunological System Pathology: Autoimmune, Amyloid, and Systemic Immune-Mediated Disease 15.6 Integumentary System Pathology: Inflammatory Dermatoses, Blistering Disorders, and Skin Neoplasms 15.7 Musculoskeletal System Pathology: Metabolic Bone Disease, Arthropathies, and Bone Neoplasms 15.8 Reproductive System Pathology: Endocrine, Inflammatory, and Neoplastic Disorders of the Reproductive Tract

10.2 Glycolysis, Pyruvate Dehydrogenase, TCA Cycle, and Oxidative Phosphorylation

Key Takeaways Explain This Topic AI

Glycolysis is a cytosolic pathway converting 1 glucose molecule into 2 pyruvate, 2 net ATP, and 2 NADH, regulated primarily by Phosphofructokinase-1 (PFK-1).

Pyruvate Dehydrogenase (PDH) complex bridges glycolysis and the TCA cycle in the mitochondrial matrix, requiring five coenzymes (TPP, FAD, NAD+, CoA, Lipoic acid) and inhibited by arsenic.

The TCA cycle oxidizes acetyl-CoA to yield 3 NADH, 1 FADH2, 1 GTP, and 2 CO2 per turn, governed by the rate-limiting enzyme Isocitrate Dehydrogenase.

Oxidative phosphorylation coupling mitochondrial electron transport (Complexes I-IV) to ATP synthesis (Complex V) creates the proton motive force, which can be blocked by specific inhibitors or dissipated as heat by uncoupling agents.

Last updated: July 2026

10.2 Glycolysis, Pyruvate Dehydrogenase, TCA Cycle, and Oxidative Phosphorylation

Central energy metabolism converts nutrient substrates into ATP through linked catabolic pathways spanning the cytoplasm and mitochondria. Understanding these pathways, their regulatory checkpoints, cellular yields, and toxicological vulnerabilities is paramount for NPLEX Part I candidates.

Glycolysis: Cytosolic Glucose Oxidation

Glycolysis is a universal cytosolic metabolic pathway that metabolizes 1 molecule of 6-carbon glucose into 2 molecules of 3-carbon pyruvate, generating a net yield of 2 ATP (via substrate-level phosphorylation) and 2 NADH .

The 10 Enzymatic Steps & Key Checkpoints

Glycolysis consists of an energy investment phase (consuming 2 ATP) and an energy generation phase (producing 4 ATP). Glucose (6C)

  • │ [1] Hexokinase / Glucokinase (Consumes 1 ATP)
  • ▼
  • Glucose-6-Phosphate
  • │ [2] Phosphoglucose Isomerase
  • ▼
  • Fructose-6-Phosphate
  • │ [3] Phosphofructokinase-1 (PFK-1) <-- RATE-LIMITING STEP! (Consumes 1 ATP)
  • ▼
  • Fructose-1,6-Bisphosphate
  • │ [4] Aldolase
  • ├───────────────────────────┐
  • ▼ ▼
  • Glyceraldehyde-3-Phosphate Dihydroxyacetone Phosphate (DHAP)
  • │ │ [5] Triose Phosphate Isomerase
  • └───◄───────────────────────┘
  • │ (x2 molecules per glucose)
  • │ [6] Glyceraldehyde-3-Phosphate DH (Produces 2 NADH total)
  • ▼
  • 1,3-Bisphosphoglycerate
  • │ [7] Phosphoglycerate Kinase (Produces 2 ATP total - Substrate Level)
  • ▼
  • 3-Phosphoglycerate
  • │ [8] Phosphoglycerate Mutase
  • ▼
  • 2-Phosphoglycerate
  • │ [9] Enolase (Inhibited by Fluoride)
  • ▼
  • Phosphoenolpyruvate (PEP)
  • │ [10] Pyruvate Kinase (Produces 2 ATP total - Substrate Level)
  • ▼
  • Pyruvate (3C x2)
  • Irreversible Glycolytic Steps & Regulation

Hexokinase vs. Glucokinase (Step 1):

Hexokinase: Expressed in most extrahepatic tissues. Low K m K_m K m ​ (high affinity for glucose), low V m a x V_{max} V ma x ​ . Strongly inhibited by its product, Glucose-6-Phosphate (G6P) , preventing excessive cellular glucose trapping when energy is abundant.

Glucokinase: Expressed exclusively in liver parenchymal cells and pancreatic β \beta β -cells. High K m K_m K m ​ (low affinity; operates efficiently only after carbohydrate-rich meals), high V m a x V_{max} V ma x ​ (capacity to clear large portal glucose loads). Not inhibited by G6P ; regulated by glucokinase regulatory protein (GKRP).

Phosphofructokinase-1 (PFK-1 - Step 3): The primary rate-limiting enzyme of glycolysis.

Positive Allosteric Effectors: High AMP , Fructose-2,6-bisphosphate (F2,6BP) . Insulin increases F2,6BP by dephosphorylating the bifunctional enzyme PFK-2/FBPase-2, stimulating PFK-1 and driving glycolysis.

Negative Allosteric Effectors: High ATP , Citrate (signals abundant energy/TCA intermediates).

Pyruvate Kinase (Step 10): Catalyzes PEP → \rightarrow → Pyruvate.

Activated by: Fructose-1,6-bisphosphate (feed-forward activation).

Inhibited by: ATP, Alanine, and Acetyl-CoA. Glucagon induces phosphorylation/inactivation in liver.

Metabolic Fates of Pyruvate

Pyruvate generated by glycolysis occupies a critical branch point depending on cellular oxygen status, organ tissue type, and metabolic demand: ┌─► Lactate (Anaerobic: LDH; re-oxidizes NADH to NAD+)

  • │
  • ├─► Acetyl-CoA (Aerobic: PDH in mitochondrial matrix)
  • Pyruvate (3-Carbon) ────┤
  • ├─► Oxaloacetate (Anaplerotic / Gluconeogenesis: Pyruvate Carboxylase)
  • │
  • └─► Alanine (Transamination: ALT; Cahill / Glucose-Alanine Cycle)

Aerobic Oxidation to Acetyl-CoA: Transported into mitochondrial matrix for oxidation by the Pyruvate Dehydrogenase (PDH) complex.

Anaerobic Reduction to Lactate: Catalyzed by Lactate Dehydrogenase (LDH) in the cytosol ( Pyruvate + NADH + H + ⇌ Lactate + NAD + \text{Pyruvate} + \text{NADH} + \text{H}^+ \rightleftharpoons \text{Lactate} + \text{NAD}^+ Pyruvate + NADH + H + ⇌ Lactate + NAD + ). Crucial in mature red blood cells (which lack mitochondria) and exercising skeletal muscle to regenerate cytosolic NAD + \text{NAD}^+ NAD + required to maintain Step 6 of glycolysis.

Transamination to Alanine: Catalyzed by Alanine Aminotransferase (ALT) using B6 (PLP). Facilitates nitrogen transport from muscle to liver via the Cahill (Glucose-Alanine) Cycle .

Carboxylation to Oxaloacetate: Catalyzed by mitochondrial Pyruvate Carboxylase (requires Biotin B7 and ATP). Serves as an anaplerotic reaction to replenish TCA intermediates or initiate gluconeogenesis.

Pyruvate Dehydrogenase (PDH) Complex

PDH is a massive multienzyme mitochondrial complex ( E 1 E_1 E 1 ​ pyruvate dehydrogenase, E 2 E_2 E 2 ​ dihydrolipoyl transacetylase, E 3 E_3 E 3 ​ dihydrolipoyl dehydrogenase) converting Pyruvate to Acetyl-CoA ( 3 C → 2 C + CO 2 3\text{C} \rightarrow 2\text{C} + \text{CO}_2 3 C → 2 C + CO 2 ​ ).

Five Mandatory Coenzymes:

  • T hiamine pyrophosphate ( B 1 B_1 B 1 ​ / TPP)
  • F lavin adenine dinucleotide ( B 2 B_2 B 2 ​ / FAD)
  • N icotinamide adenine dinucleotide ( B 3 B_3 B 3 ​ / NAD + \text{NAD}^+ NAD + )
  • C oenzyme A ( B 5 B_5 B 5 ​ / CoA)
  • Lipoic acid (Mnemonic: T ender F lorida N urse C an L ift)

Clinical / Toxicological Highlight: Arsenic poisoning binds lipoic acid covalently, inhibiting PDH (and α \alpha α -ketoglutarate DH). Causes garlic breath, watery diarrhea, skin hyperpigmentation/hyperkeratosis, QT prolongation, and severe lactic acidosis.

The Tricarboxylic Acid (TCA) Cycle

Occurring in the mitochondrial matrix, the TCA (Krebs) cycle oxidizes the 2-carbon acetyl unit of Acetyl-CoA to two molecules of CO 2 \text{CO}_2 CO 2 ​ .

Stoichiometry & Yield

For each turn of the TCA cycle (1 Acetyl-CoA derived from 1 2 \frac{1}{2} 2 1 ​ glucose molecule):

  • 3 NADH (generated by Isocitrate DH, α \alpha α -Ketoglutarate DH, Malate DH)
  • 1 FADH 2 \text{FADH}_2 FADH 2 ​ (generated by Succinate DH / Complex II)
  • 1 GTP (generated by Succinyl-CoA Synthetase via substrate-level phosphorylation)
  • 2 CO 2 \text{CO}_2 CO 2 ​

(Therefore, 1 Glucose molecule yielding 2 Acetyl-CoA generates 6 NADH, 2 FADH 2 \text{FADH}_2 FADH 2 ​ , 2 GTP, and 4 CO 2 \text{CO}_2 CO 2 ​ in the TCA cycle).

Key Regulatory Steps

Isocitrate Dehydrogenase: The rate-limiting enzyme of the TCA cycle (catalyzes Isocitrate → α \rightarrow \alpha → α -Ketoglutarate). Activated by ADP ; inhibited by ATP and NADH .

α \alpha α -Ketoglutarate Dehydrogenase: Requires the same 5 coenzymes as PDH (TPP, FAD, NAD + \text{NAD}^+ NAD + , CoA, Lipoic acid). Inhibited by Succinyl-CoA, NADH, and ATP.

Succinate Dehydrogenase: Embedded directly in the inner mitochondrial membrane as Complex II of the Electron Transport Chain.

Electron Transport Chain & Oxidative Phosphorylation

Located within the inner mitochondrial membrane, the Electron Transport Chain (ETC) oxidizes NADH \text{NADH} NADH and FADH 2 \text{FADH}_2 FADH 2 ​ , transferring electrons along protein complexes to molecular oxygen ( O 2 \text{O}_2 O 2 ​ ), the terminal electron acceptor ( 2 H + + 1 2 O 2 + 2 e − → H 2 O 2\text{H}^+ + \frac{1}{2}\text{O}_2 + 2e^- \rightarrow \text{H}_2\text{O} 2 H + + 2 1 ​ O 2 ​ + 2 e − → H 2 ​ O ).

Membrane Complexes & Proton Pumping

As electrons flow through high-affinity carriers, Complexes I, III, and IV pump protons ( H + \text{H}^+ H + ) from the matrix into the intermembrane space, generating an electrochemical proton gradient ( proton-motive force ):

Complex Name Electron Input Protons Pumped Notes

Complex I NADH Dehydrogenase / NADH-CoQ Reductase Receives 2 e − 2e^- 2 e − from NADH \text{NADH} NADH 4 H + \text{H}^+ H + pumped Contains FMN and Fe-S centers.

Complex II Succinate Dehydrogenase Receives 2 e − 2e^- 2 e − from FADH 2 \text{FADH}_2 FADH 2 ​ 0 H + \text{H}^+ H + pumped Does NOT span membrane; does not pump protons.

Coenzyme Q Ubiquinone Receives 2 e − 2e^- 2 e − from Complexes I & II N/A Mobile lipid-soluble electron carrier in membrane.

Complex III Cytochrome b c 1 bc_1 b c 1 ​ Complex Receives 2 e − 2e^- 2 e − from Coenzyme Q 4 H + \text{H}^+ H + pumped Contains Cytochromes b b b , c 1 c_1 c 1 ​ , and Rieske Fe-S center.

Cytochrome c Cytochrome c Receives 1 e − 1e^- 1 e − from Complex III N/A Mobile water-soluble protein in intermembrane space.

Complex IV Cytochrome c Oxidase Receives electrons from Cytochrome c 2 H + \text{H}^+ H + pumped Contains Cytochromes a , a 3 a, a_3 a , a 3 ​ and Cu 2 + \text{Cu}^{2+} Cu 2 + centers; transfers e − e^- e − to O 2 \text{O}_2 O 2 ​ .

Complex V ATP Synthase Driven by H + \text{H}^+ H + influx back to matrix Flow of H + \text{H}^+ H + drives F 0 / F 1 F_0/F_1 F 0 ​ / F 1 ​ rotational catalysis Synthesizes ATP \text{ATP} ATP from ADP + P i \text{ADP} + P_i ADP + P i ​ .

P/O Ratios: Oxidation of 1 NADH \text{NADH} NADH yields ≈ 2.5 \approx 2.5 ≈ 2.5 ATP; oxidation of 1 FADH 2 \text{FADH}_2 FADH 2 ​ yields ≈ 1.5 \approx 1.5 ≈ 1.5 ATP.

Pharmacological & Toxicological Inhibitors NADH ──► Complex I ──► CoQ ──► Complex III ──► Cyt c ──► Complex IV ──► O2

  • │ │ │
  • Inhibited by Inhibited by Inhibited by
  • Rotenone Antimycin A Cyanide (CN-)
  • Amobarbital Carbon Monoxide (CO)
  • Sodium Azide (N3-)

ETC Complex Inhibitors: Directly block electron flow, arresting oxygen consumption and halting proton pumping.

Complex I Inhibitor: Rotenone (pesticide), Amobarbital .

Complex III Inhibitor: Antimycin A .

Complex IV Inhibitors: Cyanide ( CN − \text{CN}^- CN − ) , Carbon Monoxide ( CO \text{CO} CO ) , Sodium Azide ( N 3 − \text{N}_3^- N 3 − ​ ) , and Hydrogen Sulfide ( H 2 S \text{H}_2\text{S} H 2 ​ S ) . Binds Fe 3 + \text{Fe}^{3+} Fe 3 + in Cytochrome a 3 a_3 a 3 ​ , halting respiration.

ATP Synthase Inhibitor: Oligomycin directly blocks the F 0 F_0 F 0 ​ proton channel of Complex V, causing an accumulation of protons in the intermembrane space, which eventually stops ETC electron flow due to steep backpressure.

Uncoupling Agents: Dissipate the intermembrane proton gradient without inhibiting electron transport. Electron transport continues rapidly, consuming O 2 \text{O}_2 O 2 ​ , but ATP synthesis ceases; the potential energy is released entirely as heat .

Synthetic Uncouplers: 2,4-Dinitrophenol (2,4-DNP) (historical diet drug causing hyperthermia, tachypnea, diaphoresis, and death), High-dose Salicylates (Aspirin overdose).

Endogenous Uncoupler: Thermogenin (UCP-1) in brown adipose tissue of newborns and hibernating mammals, providing non-shivering thermogenesis.